RC
OACC

Rangeley Capital’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Rangeley Capital’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$424K Buy
61,188
+21,156
+53% +$225K 0.41% 51
2025
Q4 		$424K Buy
40,032
+2,205
+6% +$23.3K 0.35% 58
2025
Q3 		$398K Buy
+37,827
New +$395K 0.34% 62

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Rangeley Capital's OACC Position: Q1 2026 in Review

Rangeley Capital increased its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 53% in Q1 2026, buying an estimated $225K and bringing the position to 61,188 shares worth $424K. The position accounts for 0.41% of the portfolio, ranked #51.

Rangeley Capital first reported a position in OACC in Q3 2025 and has held it in 3 quarters since. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • Rangeley Capital held 61,188 shares of Oaktree Acquisition Corp III Life Sciences worth $424K as of Q1 2026.
  • Rangeley Capital bought 21,156 Oaktree Acquisition Corp III Life Sciences shares in Q1 2026, an estimated $225K.
  • Oaktree Acquisition Corp III Life Sciences made up 0.41% of Rangeley Capital's portfolio in Q1 2026, its #51 holding.
  • Rangeley Capital first reported a position in Oaktree Acquisition Corp III Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.